What Caused Neuphoria Therapeutics Stock (NEUP) to Drop 65% Today?
Clinical Trial Update: Neuphoria Therapeutics' stock dropped significantly after the AFFIRM-1 Phase 3 trial of BNC210 for social anxiety disorder failed to meet its primary and secondary endpoints.
Future Plans: The company will cease development of BNC210 for social anxiety disorder and will reassess its potential for treating PTSD, alongside conducting a strategic review of its operations.
Stock Performance: Following the news, Neuphoria's stock fell 67.53% in pre-market trading, despite a year-to-date increase of 348.98%.
Analyst Ratings: The consensus rating for Neuphoria Therapeutics remains a Moderate Buy, with an average price target of $19.43, although these ratings may change due to the recent developments.
Get Free Real-Time Notifications for Any Stock
Analyst Views on NEUP
About NEUP
About the author
Neuphoria Urges Shareholders to Support Director Nominees for Maximum Value
- Shareholder Voting Recommendation: Neuphoria Therapeutics Inc. urges shareholders to support its director nominees, particularly Peter Miles Davies and David Wilson, to ensure maximum shareholder value during the strategic review process.
- ISS Recommendation: Institutional Shareholder Services (ISS) issued a report recommending shareholders vote for Neuphoria's nominees, noting that the board acted appropriately in response to the clinical trial failure and capital raise efforts.
- Successful Capital Raise: The board proactively raised capital ahead of the Phase 3 trial data readout, strengthening the company's balance sheet and providing a solid financial foundation for the upcoming strategic review.
- Commitment to Transparency: Neuphoria's board has committed to maintaining transparency throughout the strategic review process and has provided recent updates to shareholders, aiming to bolster confidence in the company's future direction.
Nasdaq Rises 1%; Procter & Gamble Reports Positive Earnings
U.S. Stock Market Performance: U.S. stocks opened higher, with the Nasdaq Composite gaining 1% and the Dow and S&P 500 also showing positive movements. Information technology shares rose by 1.3%, while materials stocks fell by 0.3%.
Procter & Gamble Earnings Report: Procter & Gamble reported better-than-expected earnings and sales for Q3, raising its fiscal 2026 guidance for adjusted EPS and sales, surpassing analyst estimates.
Notable Stock Movements: Wellgistics Health saw a significant increase of 183% after a partnership announcement, while Genenta Science surged 145% due to a collaboration expansion. Conversely, Picard Medical's shares dropped 72%.
Global Market Overview: European shares were mixed, with slight gains in some indices, while Asian markets mostly closed higher. Economic indicators showed an increase in the S&P Global services and manufacturing PMIs for October.
